Erythema resulting from suberythemogenic doses of ultraviolet radiation and methotrexate.
A tender diffuse erythema developed in a 47-year-old man who had psoriasis when he was treated with either suberythemogenic oral methoxsalen photochemotherapy or ultraviolet (UV)-B phototherapy and intramuscular methotrexate (MTX). Phototests with middle- and long-wavelength UV fluorescent lamps indicated that the sequence and timing of each therapeutic exposure were important to the development of the erythema. Histologic examination of the erythematous area demonstrated an increased number of pyknotic keratinocytes (sunburn cells) in the upper epidermis. It is possible that MTX prevented the repair of DNA damage caused by UV exposure, leading to the appearance of the sunburn cells and erythema. Care must be exercised when using UV radiation and MTX in combination.
D004260:DNA Repair / Q000187:drug effects; D004890:Erythema / Q000209:etiology* / Q000473:pathology; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects*; D008875:Middle Aged; D011701:PUVA Therapy / Q000009:adverse effects*; D010778:Photochemotherapy / Q000009:adverse effects*; D011565:Psoriasis / Q000628:therapy*; D012867:Skin / Q000473:pathology; D013997:Time Factors; D014467:Ultraviolet Therapy / Q000009:adverse effects*
D008727:Methotrexate